There are many diseases for which there are no vaccines and others for which the vaccines are not optimal or have significant side effects. The objectives of this project are to characterize viral antigens, determine targets of humoral and cell mediated immunity, and use this information to develop candidate vaccines. Live recombinant viral vaccines, DNA vaccines and recombinant protein vaccines are being developed. The vaccines are first tested in small animals and then in non-human primates. Presently we are working on vaccinia virus-vectored vaccines for HIV.

Project Start
Project End
Budget Start
Budget End
Support Year
30
Fiscal Year
2013
Total Cost
$640,709
Indirect Cost
City
State
Country
Zip Code
Goepfert, Paul A; Elizaga, Marnie L; Seaton, Kelly et al. (2014) Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 210:99-110
Kwa, Suefen; Lai, Lilin; Gangadhara, Sailaja et al. (2014) CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol 88:9579-89
Dong, Biao; Moore, Andrea R; Dai, Jihong et al. (2013) A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy. Nucleic Acids Res 41:6609-17
Moss, Bernard (2013) Reflections on the early development of poxvirus vectors. Vaccine 31:4220-2
Melamed, Sharon; Wyatt, Linda S; Kastenmayer, Robin J et al. (2013) Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants. Vaccine 31:4569-77
Schell, John; Rose, Nina F; Fazo, Nicole et al. (2009) Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine 27:979-86
Earl, Patricia L; Cotter, Catherine; Moss, Bernard et al. (2009) Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 27:5885-95
Gudmundsdotter, Lindvi; Nilsson, Charlotta; Brave, Andreas et al. (2009) Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 27:4468-74
Wyatt, Linda S; Earl, Patricia L; Xiao, Wei et al. (2009) Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 83:7176-84
Zhao, Jun; Lai, Lilin; Amara, Rama Rao et al. (2009) Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 83:4102-11

Showing the most recent 10 out of 12 publications